Latest From AnTolRx Inc.
In Q3, biopharma financing totaled $7.4 billion, a large proportion of which was by rare disease developers; among the highlights in the $23 billion in M&As was Allergan's buying spree, including two NASH companies. Just over $20 billion went into biopharma alliance dealmaking, and neurology assets attracted many of the dollars.
Moderna and Intarcia lead recent fundraisings; big pharma backing includes Novartis leading Series A for Inflazome and Pfizer for diabetes play Antolrx. Derived from Strategic Transactions, Informa’s premium source for tracking life sciences deal activity, the Venture Funding Deals column provides a comprehensive monthly review of emerging biopharmaceutical companies that have received venture funding. This month’s column covers deals announced August through September 2016.
A review of biopharma start-up dealmaking and financing from July through September 2016, based on data from Strategic Transactions.
Derived from Strategic Transactions, Informa’s premium source for tracking life sciences deal activity, the Dealmaking column is a survey of recent health care transactions listed by relevant industry segment – In Vitro Diagnostics, Medical Devices, and Pharmaceuticals – and then categorized by type – Acquisition, Alliance, or Financing. This month’s column covers deals announced in September 2016.
- Nanotechnology, Chips, etc.
- Therapeutic Areas
- Immune Disorders
- Metabolic Disorders
- North America
- Company Type
- Parent & Subsidiaries
- AnTolRx Inc.
- Senior Management
Mark Carthy, CEO
Jessica Kenison-White, Sr. Scientist
- Contact Info
Phone: (617) 945-8468
One Kendall Sq., Bldg. 1400 West
Cambridge, MA 02139
All set! This article has been sent to email@example.com.
All fields are required. For multiple recipients, separate email addresses with a semicolon.